Outlook Therapeutics’ Lytenava Nears FDA Verdict as Shares Skyrocket — But RSI Flashes Caution

FDA accepts Outlook Therapeutics' resubmission for Lytenava, the first standardized ophthalmic bevacizumab, with a decision due July 29, 2026. Stock surges 57% but RSI at 86 signals overbought.

The push to bring a standardized ophthalmic bevacizumab to market has entered its final straight. For years, retina specialists have relied on repurposed cancer drug bevacizumab for conditions like wet age-related macular degeneration, mixing it in pharmacy compounding rooms under off-label use — a practice that carries contamination and dosing variability risks. Outlook Therapeutics aims to end that grey area with Lytenava, a formulation specifically designed for the eye, and the US Food and Drug Administration has just set a date for the decision.

The regulator has accepted the company’s resubmitted application as a Class 1 review, a designation that fast-tracks the process after prior rejections — most recently earlier this year. The final verdict is expected on 29 July 2026. “This is a great day for patients,” said CEO Bob Jahr in a statement, as the management team simultaneously gears up for a commercial launch. If approved, Lytenava would become the first officially authorised ophthalmic variant of bevacizumab, replacing the current off-label workaround with a regulated standard.

Investors have responded with exuberance. The stock closed Wednesday at USD 1.65, gaining just over five percent on the session, and extended those gains by another four percent in pre-market trading on Thursday. Since the FDA confirmed the clinical data underpinning the application, the shares have surged a staggering 57 percent.

Yet technical signals urge caution. The Relative Strength Index has climbed to 86, a level widely regarded as deeply overbought. The market appears to have priced in a significant portion of the positive outcome well ahead of the actual regulatory decision. The high RSI warns that a pullback could be imminent if sentiment shifts or if the July 29 deadline yields any negative surprises.

The timing places Outlook’s fate in a broader tapestry of biotech volatility. The sector has been swinging wildly: rival Graybug Vision jumped nearly 25 percent on Thursday to USD 1.14 on heavy volume of almost three million shares. Spero Therapeutics secured an FDA nod for its antibiotic Utebzi, sending its stock up by roughly 26 percent after hours. uniQure saw a 70 percent leap after the FDA flagged an accelerated pathway for its gene therapy, while Spyre Therapeutics added 16.5 percent on positive study data.

Within the ophthalmic space specifically, the competitive landscape is shifting. Nicox recently received a preliminary positive vote from Chinese regulators for its glaucoma eye drops, with a US filing planned for summer 2026. Oculis missed primary endpoints in a key Phase 3 trial, and Ocular Therapeutix does not expect to submit its own competitor application until late 2026. Merck, meanwhile, has opened a new clinical study in the same therapeutic area. The FDA’s growing willingness to accept a single controlled trial plus confirmatory evidence for certain approvals — a policy designed to speed patient access — could work in Lytenava’s favour.

Looking ahead, the pharmaceutical calendar is dense. Additional FDA verdicts for major players including Roche, Merck and Sanofi are due by February 2026. But for Outlook Therapeutics, everything hinges on that single July date. A green light would fundamentally redraw the US distribution model for ophthalmic bevacizumab and secure the company’s financial structure. With the stock already up 57 percent and the RSI flashing red, the market has placed its bet — but the real reckoning still lies two months away.